PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma
PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma
复制标题
DOI：
10.1007/s00259-012-2124-x
复制
发表时间：
2012-08-01
影响因子：
9.1
通讯作者：
Verburg, Frederik A.
中科院分区：
文献类型：
--
作者：
Haenscheid, Heribert;Sweeney, Reinhart A.;Verburg, Frederik A.
为了探讨脑膜瘤多肽受体放射性核素治疗(PRRT)中肿瘤对放射性核素的摄取是否可以通过GA-68标记的生长抑素类似物进行PET扫描来预测。在这项初步试验中，11例脑膜瘤患者接受了7.4 GBq Lu-177-DOTATOC或Lu-177-DOTATE的PRRT，然后进行外照射。第二次PET扫描计划在治疗后3个月进行。在PRRT期间，采集了多次全身扫描和头部和颈部的SPECT/CT扫描，并使用这些扫描来确定肿瘤内放射性核素摄取最高的体素的动力学和剂量。脑膜瘤的最大标准摄取值(SUVmax)为13.7(范围4.3~68.7)，0.11 CMA(3)的最大摄取分数中位数为23.4×10(-6)(范围0.4×10(-6)~68.3×10(-6))。在摄取最高的体素中，SUVmax和PRRT放射性核素肿瘤滞留有很强的相关性(Spearman等级检验，P<；0.01)。剔除1例PET和PRRT的生物动力学差异较大的患者和1例资料不完整的患者，直线回归分析显示SUVmax与治疗性摄取显著相关(r=0.95)，SUVmax与PRRT的最大体素剂量显著相关(r=0.76)。观测到的绝对偏差与回归预测值的中位数为5.6x10(-6)(最大9.3x10(-6))，体素部分放射性核素摄取的中位数为0.40GyPbq(最大0.85GyPbq)Lu-177。使用Ga-68标记的生长抑素类似物进行PET可以在治疗前评估脑膜瘤PRRT中肿瘤的放射性核素摄取，并估计可达到的剂量。
To investigate whether the tumour uptake of radionuclide in peptide receptor radionuclide therapy (PRRT) of meningioma can be predicted by a PET scan with Ga-68-labelled somatostatin analogue.In this pilot trial, 11 meningioma patients with a PET scan indicating somatostatin receptor expression received PRRT with 7.4 GBq Lu-177-DOTATOC or Lu-177-DOTATATE, followed by external beam radiotherapy. A second PET scan was scheduled for 3 months after therapy. During PRRT, multiple whole-body scans and a SPECT/CT scan of the head and neck region were acquired and used to determine the kinetics and dose in the voxel with the highest radionuclide uptake within the tumour. Maximum voxel dose and retention of activity 1 h after administration in PRRT were compared to the maximum standardized uptake values (SUVmax) in the meningiomas from the PET scans before and after therapy.The median SUVmax in the meningiomas was 13.7 (range 4.3 to 68.7), and the maximum fractional radionuclide uptake in voxels of size 0.11 cmA(3) was a median of 23.4 x 10(-6) (range 0.4 x 10(-6) to 68.3 x 10(-6)). A strong correlation was observed between SUVmax and the PRRT radionuclide tumour retention in the voxels with the highest uptake (Spearman's rank test, P < 0.01). Excluding one patient who showed large differences in biokinetics between PET and PRRT and another patient with incomplete data, linear regression analysis indicated significant correlations between SUVmax and the therapeutic uptake (r = 0.95) and between SUVmax and the maximum voxel dose from PRRT (r = 0.76). Observed absolute deviations from the values expected from regression were a median of 5.6 x 10(-6) (maximum 9.3 x 10(-6)) for the voxel fractional radionuclide uptake and 0.40 Gy per GBq (maximum 0.85 Gy per GBq) Lu-177 for the voxel dose from PRRT.PET with Ga-68-labelled somatostatin analogues allows the pretherapeutic assessment of tumour radionuclide uptake in PRRT of meningioma and an estimate of the achievable dose.